DL25

DL25 binds with highest affinity to M. tuberculosis LysA (Rv1293) with a binding energy of -10.30 kcal/mol, followed by SecA1 (Rv3240) and LpdA (Rv3303c), indicating potential multi-target anti-mycobacterial activity^[1].
DL25 (100 ns) forms a stable, compact complex with M. tuberculosis LysA (Rv1293) during MD simulation, with reduced protein flexibility in the binding pocket and stabilizing hydrogen bonds^[1].
DL25 (2-100 μg/mL; 10 min preincubation) inhibits recombinant M. tuberculosis DHQS-associated biochemical activity with an apparent IC₅₀ of 5.0 μg/mL^[2].
DL25 stably binds to the active site of M. tuberculosis DHQS, forming key interactions with substrate recognition residues, as supported by molecular docking and 100 ns MD simulations^[2].
DL25 inhibits the growth of M. tuberculosis H37AlRa and H37Rv with an MIC₉₀ of 1-2 μg/mL and MBC₉₉ of 2 μg/mL, and non-M. tuberculosis mycobacteria with an MIC₉₀ of 2-4 μg/mL and MBC₉₉ of 8 μg/mL^[1].
DL25 (7 days) inhibits and kills autoluminescent M. tuberculosis H37Ra (AlRa) in a concentration-dependent manner, with bactericidal activity observed at concentrations of 2×MIC (0.62 μM) and higher over 7 days of incubation^[1].
DL25 (2-4 μg/mL; 3-7 days) potently inhibits growth of M. tuberculosis AlRa, M. tuberculosis AlRv, and M. smegmatis AlMs with an MIC of 2 μg/mL, and M. marinum AlMm and M. abscessus AlMab with an MIC of 4 μg/mL^[2].
DL25 (0.5-16 μg/mL; 5 days) inhibits intracellular M. tuberculosis AlRa in differentiated THP-1 macrophages with an intracellular MIC of 4 μg/mL, and has a moderate selectivity index of 4-8^[2].
DL25 (based on MIC of 2 μg/mL; 7 days) exhibits partial synergy with Rifampicin (HY-B0272), Ethambutol (HY-B0535), Linezolid (HY-10394), Bedaquiline (HY-14881), and Ethionamide (HY-B0276) against M. tuberculosis AlRa, with no antagonistic interactions observed with any tested antitubercular agent^[2].
DL25 (0.5-8 μg/mL; up to 60 h/6 days) demonstrates concentration- and time-dependent bactericidal activity against M. tuberculosis AlRa, M. marinum AlMm, M. abscessus AlMab, and M. smegmatis AlMs^[2].
DL25 (2-8 μg/mL; 3 days) has reduced efficacy against aroB-overexpressing M. smegmatis mc2155, increasing the MIC from 2 μg/mL to 4-8 μg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.